Pfizer Corporation

Epizyme, Inc.

Pfizer Products Inc.

Other

Glaxosmithkline Intellectual Property Development Limited

Michael John Munchhof

Richard Chesworth

Kenneth William Duncan

Lei Jin

Paula Ann Boriack-Sjodin

Mark Edward Flanagan

Todd A Blumenkopf

Laura Cook Blumberg

Megan Alene Cloonan Foley

Kevin Wayne Kuntz

Lorna Helen Mitchell

Lawrence Alan Reiter

Darren Martin Harvey

James Edward John Mills

Christopher Scott Jones

Susan D La Greca

Qifang Li

Robert L Dow

John Emmerson Campbell

Andrew Simon Bell

Kentaro Futatsugi

John W Lampe

Michael P Deninno

Daniel Wei-Shung Kung

Vincent Mascitti

Matthew Arnold Marx

Ton Rene Vries

Andrei Shavnya

Susan Beth Sobolov-Jaynes

Michael Thomenius

Elayne Penebre

Olena I Barbash

Glenn E Wilcox

Megan Alene Foley

Christian Koecher

Ton Vries

Ralph Pelton Robinson

Kim Francis Mcclure

Bruce Allen Lefker

Glenn Ernest Wilcox

Susan La Greca

Robert Lee Dow

Compounds of Formula I: (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R, R, G1, G2, Q, Q, Q, and (II) are defined as set forth in the specification, as are uses of compounds of Formula I to treat a disease, disorder, or condition such as cancer in a subject.

Substituted indoles and methods of use thereof

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 

PRMT5 inhibitors and uses thereof

Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof. Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof.

The present disclosure provides substituted piperidine compounds having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer. 

Substituted piperidine compounds

The present disclosure provides substituted isoxazole carboxamide compounds having Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R, R, A, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer. 

Isoxazole carboxamide compounds

PRMT5 inhibitors and uses therof

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 

Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof

The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer. 

Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer

Described herein are compounds of formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. 

The present disclosure provides substituted cyclohexylamine compounds having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R, R, R, R, R, R, R, and Rare defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer. 

Substituted isoxazoles for treating cancer

PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof

Growing community of inventors

Salem, CT, United States of America

Michael John Munchhof